Private Equity
1 min read · 22 May 2018
San Francisco-based Luma Health, which helps to connect patients with healthcare providers, has raised $6.33 million in a Series A round funding. U.S. Venture Partners led the round, which included continued participation from the Stanford-StartX Fund and additional existing investors. The company, founded in 2015, has now raised $9.7 million in total funding. As part of the Series A round, Dafina Toncheva, a partner at USVP, has joined the board.
4 min read · 22 May 2018
Honor, a home care company, has secured $50 million in Series C funding. Naspers Ventures led the round.
4 min read · 22 May 2018
4 min read · 22 May 2018
7 min read · 22 May 2018
St. Louis, Missouri-based venture firm Cultivation Capital has raised over $15 million for its second life sciences fund targeted at $30 million, according to an SEC filing. And in a separate SEC filing, the firm also raised $33.45 million for its second tech fund targeted at $40 million.
1 min read · 21 May 2018
4 min read · 21 May 2018
Indianapolis-based Scioto Biosciences, a developer of "innovative therapies to transform the delivery of microbiome therapeutics," has raised $1.8 million in Series A financing. The investors included BioCrossroads, Elevate Ventures and Rev1 Ventures.
1 min read · 21 May 2018
Cambridge, Massachusetts-based FogPharma, a developer of new treatments for cancer and other life-threatening diseases, has secured $66 million in Series B financing. The lead investor was 6 Dimensions Capital. Other investors that participated in the round included GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Leerink Partners Deerfield Management, Boyu Capital and WuXi AppTec Corporate Ventures.
1 min read · 21 May 2018
Santa Clarita, California-based SetPoint Medical, a biomedical technology company, has named Ankit Shah as senior director of commercialization and marketing. Previously, Shah was senior director of marketing and business development at Intersect ENT. SetPoint's backers include Morgenthaler Ventures, New Enterprise Associates, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific.
3 min read · 21 May 2018